Development of Key Technologies for Real-Time Diagnosis, Surveillance and Interventionof Resistant-Bacterial Infections Based on Nanopore Sequencing

拟议的项目旨在解决对抗AMR的两个主要障碍，即新药和新诊断。新的诊断将利用英国尖端技术（牛津纳米孔测序）在6小时内提供前所未有的信息深度的测试结果，而目前的技术通常需要24-48小时。开发新药的方法需要开发“增效剂”--能够渗透细菌细胞壁的药剂，从而允许使用已建立的抗菌化合物。该项目中的增效剂针对革兰氏阴性（OPT-200）和革兰氏阳性（OPT-1）细菌，两者都具有代表一流抗菌计划的新颖作用模式。本项目的重点将是医院获得性肺炎（HAP）和HAP呼吸机获得性肺炎（VAP）的子集。HAP/VAP是世界范围内的重要感染，是发病率、死亡率和住院时间增加的主要原因，导致医疗费用上升。本项目的长期目标是提供HAP/VAP的快速诊断技术，该技术可与增效剂治疗方案相结合。财务汇总表-如何填写本部分

The proposed project aims to tackle two of the major hurdles in the fight against AMR, new drugs and newdiagnostics. The new diagnostics will utilise cutting edge UK technology (Oxford Nanopore sequencing) toprovide test results with unprecedented depth of information within 6 hours as opposed to the currenttechnologies which routinely take 24-48 hours. The approach to new drugs entails developing "Potentiators" -agents that can permeabilise the cell wall of bacteria allowing the use of established antibacterial compounds.The Potentiators in this project target Gram-negative (OPT-200) and Gram-positive (OPT-1) bacteria and bothhave novel modes of actions representing first-in-class antibacterial programmes. The focus of this project willbe on Hospital Acquired Pneumonia (HAP) and subset of HAP Ventilator Acquired Pneumonia (VAP). HAP/VAPare important infections throughout the world and are a major cause of morbidity, mortality and increases inhospital stay resulting in escalation of healthcare costs. The long-term goals of this project are to provide rapiddiagnosis technology for HAP/VAP that can be combined with a potentiator treatment regime.Finance Summary Table – How to complete this section